Granted Patent
B2
US 12,415,796 · App. 18/386,139 · Granted Sep 16, 2025
Inhibitors of (αv)(β6) integrin
Inventors:
Mark Brewer (Wallingford, GB); Matthew G. Bursavich (Needham, MA); Aleksey I. Gerasyuto (Flemington, NJ); Kristopher N. Hahn (Medford, MA); Bryce A. Harrison (Framingham, MA); Kyle D. Konze (Katonah, NY); Fu-Yang Lin (Sudbury, MA); Blaise S. Lippa (Newton, MA); Alexey A. Lugovskoy (Belmont, MA); Bruce N. Rogers (Belmont, MA); Mats A. Svensson (New York, NY); Dawn M. Troast (Bedford, MA)
Assignee:
Morphic Therapeutic, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.
Claims (12)
1. A compound selected from:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein the compound is selected from:
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition, comprising a compound of claim 1 ; and pharmaceutically acceptable excipient.
6. A pharmaceutical composition, comprising a compound of claim 2 ; and pharmaceutically acceptable excipient.
7. A pharmaceutical composition, comprising a compound of claim 3 ; and pharmaceutically acceptable excipient.
8. A pharmaceutical composition, comprising a compound of claim 4 ; and pharmaceutically acceptable excipient.
Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 27, 2024
From: HARRISON, BRYCE A.; HAHN, KRISTOPHER N.; LIN, FU-YANG; LIPPA, BLAISE S.; LUGOVSKOY, ALEXEY A.; ROGERS, BRUCE N.; TROAST, DAWN M.; BURSAVICH, MATTHEW G.
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 067861/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 27, 2024
From: BREWER, MARK; GERASYUTO, ALEKSEY I.; KONZE, KYLE D.; SVENSSON, MATS A.
To: SCHR¿DINGER, INC.
Reel/Frame 067861/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 27, 2024
From: SCHR¿DINGER, INC.
To: SCHR¿DINGER, LLC
Reel/Frame 067861/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 27, 2024
From: MORPHIC THERAPEUTIC, INC.
To: LAZULI, INC.
Reel/Frame 067861/0398 →
MERGER
Recorded Jun 27, 2024
From: LAZULI, INC.
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 067861/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 27, 2024
From: SCHR¿DINGER, LLC
To: MORPHIC THERAPEUTIC, INC.
Reel/Frame 067907/0699 →
Continuity (4)
Continuation
16489628
Provisional Application
62464693
· Feb 28, 2017
References Cited (228)
US 5952341A
· Duggan et al.
· 1999
[cited by applicant]
US 6017926A
· Askew et al.
· 2000
[cited by applicant]
US 6048861A
· Askew et al.
· 2000
[cited by applicant]
US 6069143A
· Ali et al.
· 2000
[cited by applicant]
US 6232308B1
· Askew
· 2001
[cited by applicant]
US 6358970B1
· Duggan et al.
· 2002
[cited by applicant]
US 6723711B2
· Biediger et al.
· 2004
[cited by applicant]
US 8716226B2
· Ruminski et al.
· 2014
[cited by applicant]
US 9572801B2
· Askew et al.
· 2017
[cited by applicant]
US 20010034445A1
· Ali et al.
· 2001
[cited by applicant]
US 20020010176A1
· Askew et al.
· 2002
[cited by applicant]
US 20020035127A1
· Head et al.
· 2002
[cited by applicant]
US 20040043988A1
· Khanna et al.
· 2004
[cited by applicant]
US 20080045521A1
· Arnould et al.
· 2008
[cited by applicant]
US 20120289481A1
· O'Neil et al.
· 2012
[cited by applicant]
US 20140349968A1
· O'Neil et al.
· 2014
[cited by applicant]
US 20180008583A1
· Fukunaga et al.
· 2018
[cited by applicant]
US 20180244648A1
· Harrison et al.
· 2018
[cited by applicant]
US 20200071322A1
· Harrison et al.
· 2020
[cited by applicant]
US 20200354359A1
· Harrison et al.
· 2020
[cited by applicant]
US 20230219949A1
· Harrison et al.
· 2023
[cited by applicant]
CN 101861319A
· 2010
[cited by applicant]
EP 0537696A1
· 1993
[cited by applicant]
EP 0623615A1
· 1994
[cited by applicant]
EP 0796855A1
· 1997
[cited by applicant]
EP 2221308A1
· 2010
[cited by applicant]
WO WO199310091A2
· 1993
[cited by applicant]
WO WO9314077A1
· 1993
[cited by applicant]
WO WO9724122A1
· 1997
[cited by applicant]
WO WO9724124A1
· 1997
[cited by applicant]
WO WO9725323A1
· 1997
[cited by applicant]
WO WO9726250A1
· 1997
[cited by applicant]
WO WO9736871A1
· 1997
[cited by applicant]
WO WO9808840A1
· 1998
[cited by applicant]
WO WO9818460A1
· 1998
[cited by applicant]
WO WO9846220A1
· 1998
[cited by applicant]
WO WO1998044797A1
· 1998
[cited by applicant]
WO WO1999026945A1
· 1999
[cited by applicant]
WO WO1999030709A1
· 1999
[cited by applicant]
WO WO1999030713A1
· 1999
[cited by applicant]
WO WO1999031061A1
· 1999
[cited by applicant]
WO WO1999031099A1
· 1999
[cited by applicant]
WO WO2000006169A1
· 2000
[cited by applicant]
WO WO2000031067A1
· 2000
[cited by applicant]
WO WO2000037487A1
· 2000
[cited by applicant]
WO WO2000072801A2
· 2000
[cited by applicant]
WO WO2000073260A1
· 2000
[cited by applicant]
WO WO2000078317A1
· 2000
[cited by applicant]
WO WO2001005810A2
· 2001
[cited by applicant]
WO WO2001023357A2
· 2001
[cited by applicant]
WO WO2001044194A2
· 2001
[cited by applicant]
WO WO2001053262A1
· 2001
[cited by applicant]
WO WO2001053297A1
· 2001
[cited by applicant]
WO WO2001096334A2
· 2001
[cited by applicant]
WO WO2002016328A1
· 2002
[cited by applicant]
WO WO2002022124A1
· 2002
[cited by applicant]
WO WO2002022615A1
· 2002
[cited by applicant]
WO WO2002022616A2
· 2002
[cited by applicant]
WO WO02060438A1
· 2002
[cited by applicant]
WO WO2002074730A1
· 2002
[cited by applicant]
WO WO2002090325A2
· 2002
[cited by applicant]
WO WO2003066594A2
· 2003
[cited by applicant]
WO WO2004020435A1
· 2004
[cited by applicant]
WO WO2006024699A1
· 2006
[cited by applicant]
WO WO2008157162A1
· 2008
[cited by applicant]
WO WO2014015054A1
· 2014
[cited by applicant]
WO WO2014154725A1
· 2014
[cited by applicant]
WO WO2014154809A1
· 2014
[cited by applicant]
WO WO2015103643A2
· 2015
[cited by applicant]
WO WO2015150557A1
· 2015
[cited by applicant]
WO WO2015179823A2
· 2015
[cited by applicant]
WO WO2016022851A1
· 2016
[cited by applicant]
WO WO2016046225A1
· 2016
[cited by applicant]
WO WO2016046226A1
· 2016
[cited by applicant]
WO WO2016046230A1
· 2016
[cited by applicant]
WO WO2016046241A1
· 2016
[cited by applicant]
WO WO2016176532A1
· 2016
[cited by applicant]
WO WO2017117538A1
· 2017
[cited by applicant]
WO WO2017158072A1
· 2017
[cited by applicant]
WO WO2017162570A1
· 2017
[cited by applicant]
WO WO2017162572A1
· 2017
[cited by applicant]
WO WO2018009501A1
· 2018
[cited by applicant]
WO WO2018049068A1
· 2018
[cited by applicant]
WO WO2018085552A1
· 2018
[cited by applicant]
WO WO2018085578A1
· 2018
[cited by applicant]
WO WO2018089353A1
· 2018
[cited by applicant]
WO WO2018089355A1
· 2018
[cited by applicant]
WO WO2018089357A1
· 2018
[cited by applicant]
WO WO2018089358A1
· 2018
[cited by applicant]
WO WO2018089360A1
· 2018
[cited by applicant]
WO WO2018119087A1
· 2018
[cited by applicant]
WO WO2018132268A1
· 2018
[cited by applicant]
WO WO2018160521A2
· 2018
[cited by applicant]
WO WO2018160522A1
· 2018
[cited by applicant]
WO WO2019173653A1
· 2019
[cited by applicant]
WO WO2020006315A1
· 2020
[cited by applicant]
WO WO2020009889A1
· 2020
[cited by applicant]
WO WO2020047207A1
· 2020
[cited by applicant]
WO WO2020047208A1
· 2020
[cited by applicant]
WO WO2020047239A1
· 2020
[cited by applicant]
WO WO2020076862A1
· 2020
[cited by applicant]
WO WO2020081154A1
· 2020
[cited by applicant]
WO WO2020210404A1
· 2020
[cited by applicant]
WO WO2020047207A8
· 2020
[cited by applicant]
Anderson et al., “The discovery of an orally bioavailable pan-#v integrin inhibitor for idiopathic pulmonary fibrosis,” J. Med. Chem., Just Accepted Manuscript, (2019).
[cited by applicant]
Bennet et al., “Cecil Textbook of Medicine,” 20th Edition, 1:1004-1010 (1996).
[cited by applicant]
Brashear et al., “Non-Peptide α
[cited by applicant]
Breslin et al., “Nonpeptide α
[cited by applicant]
Coleman et al., “Nonpeptide α
[cited by applicant]
Cui et al., “In Vitro and In Vivo Metabolism of a Potent and Selective Integrin α
[cited by applicant]
Database Accession No. 1380858-49-0., Database Registry [Online] Chemical Abstracts Service: XP002799454 (2012).
[cited by applicant]
Database Accession No. 1380909-02-3., Database Registry [Online] Chemical Abstracts Service: XP002799455 (2012).
[cited by applicant]
Database Accession No. 1380948-25-3., Database Registry [Online] Chemical Abstracts Service: XP002799456 (2012).
[cited by applicant]
Database Accession No. 1380999-27-8., Database Registry [Online] Chemical Abstracts Service: XP002799457 (2012).
[cited by applicant]
Database Accession No. 1571616-43-7., Database Registry [Online] Chemical Abstracts Service: XP002799458 (2014).
[cited by applicant]
Database Accession No. 1623225-85-3., Database Registry [Online] Chemical Abstracts Service: XP002799459 (2014).
[cited by applicant]
Database Accession No. 1837357-51-3., Database Registry [Online] Chemical Abstracts Service: XP002799460 (2015).
[cited by applicant]
Database Accession No. 1838839-35-2., Database Registry [Online] Chemical Abstracts Service: XP002799461 (2015).
[cited by applicant]
Database Accession No. 1940788-29-3., Database Registry [Online] Chemical Abstracts Service: XP002799462 (2016).
[cited by applicant]
Database Accession No. 2038980-05-9., Database Registry [Online] Chemical Abstracts Service: XP002799463 (2016).
[cited by applicant]
Database Registry, Chemical Abstracts Services, CAS Registry No. 1155165-04-0 (Entered STN: Oct. 6, 2009).
[cited by applicant]
Dermeret et al., “Another Anniversary for the War on Cancer,” Bio/Technology, 12:320 (1994).
[cited by applicant]
Duggan et al., “Nonpeptide α
[cited by applicant]
Extended European Search Report for EP Application No. 18761396.3 mailed Jul. 2, 2020.
[cited by applicant]
Extended European Search Report for EP Application No. 19853732.6 dated Jul. 15, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 20190341.6 dated Sep. 28, 2020.
[cited by applicant]
Extended European Search Report for EP Application No. 22173105.2 dated Aug. 18, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 22189738.2 dated Jan. 26, 2023.
[cited by applicant]
Extended European Search Report for EP Application No. 22205911.5 mailed Mar. 5, 2023.
[cited by applicant]
Extended European Search Report for EP Application No. EP 18760393.1 dated Jul. 14, 2020.
[cited by applicant]
Extended European Search Report for EP Application No. EP 19194490 dated Dec. 10, 2019.
[cited by applicant]
Extended European Search Report in EP Application No. 19856339.7 dated Apr. 25, 2022.
[cited by applicant]
Extended European Search Report in EP Application No. 19873423.8 dated Apr. 28, 2022.
[cited by applicant]
Freshney et al., “Culture of Animal Cells, A Manual of Basic Technique,” 4, (1983).
[cited by applicant]
Goodman et al., “Nanomolar Small Molecule Inhibitors for α
[cited by applicant]
Hall et al., “Characterisation of a novel, high affinity and selective α
[cited by applicant]
Hatley et al., “An αv-RGD integrin inhibitor toolbox: drug discovery insight, challenges and opportunities,” Angew. Chem., 57(13): 3298-3321 (2017).
[cited by applicant]
Hutchinson et al., “Nonpeptide α
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP00/06188 mailed May 31, 2001.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP02/01836 mailed Oct. 14, 2002.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2003/000327 mailed Dec. 3, 2003.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2014/056167 mailed Sep. 29, 2015.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP99/09842 mailed Jan. 12, 2001.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/FI2005/050305 mailed Feb. 28, 2007.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/GB00/02020 mailed Sep. 19, 2001.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/GB00/04831 mailed Oct. 1, 2002.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US00/14901 mailed Mar. 28, 2001.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US00/16849 mailed Jun. 29, 2001.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US00/26537 mailed Jan. 1, 2002.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US01/01298 mailed Oct. 8, 2001.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US01/01953 mailed Sep. 8, 2001.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US01/28238 mailed Jul. 31, 2002.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US01/28404 mailed Apr. 25, 2002.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US01/42146 mailed Sep. 5, 2002.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US02/13457 mailed Jul. 22, 2003.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/048734 dated Mar. 2, 2021.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/048737 dated Mar. 2, 2021.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/048738 dated Mar. 2, 2021.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/048782 dated Mar. 2, 2021.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US/18/19838 mailed Aug. 8, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US18/19839 mailed Aug. 9, 2018.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/048734 mailed Mar. 20, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/048737 dated Dec. 27, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/048738 mailed Jan. 7, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/048782 mailed Dec. 27, 2019.
[cited by applicant]
International Search Report for International Application No. PCT/US2019/055252 mailed Jan. 23, 2020.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2019/048737 dated Oct. 11, 2019.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2019/048738 dated Oct. 11, 2019.
[cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2019/048782 dated Oct. 11, 2019.
[cited by applicant]
Kinney el al., “Suzuki-Miyaura Approach to JNJ-26076713, an Orally Active Tetrahydroquinoline-Containing α
[cited by applicant]
Macdonald et al., “Passing on the medicinal chemistry baton: training undergraduates to be industry-ready through research projects between the University of Nottingham and GlaxoSmithKline,” Drug Discovery Today, 21(6):…
[cited by applicant]
Maden et al., “Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin α
[cited by applicant]
Meissner et al., “Nonpeptide avβ3 antagonists. Part 2: constrained glycyl amides derived from the RGD tripeptide,” Bioorganic & Medicinal Chemistry Letters, 12(1): 25-29 (2002).
[cited by applicant]
Notice of Allowance dated Mar. 31, 2023 for U.S. Appl. No. 17/239,045 (7 pages).
[cited by applicant]
Peng et al., “Integrin α
[cited by applicant]
Perkins et al., “Non-peptide α
[cited by applicant]
Pickarski et al., “Orally active avβ3 integrin inhibitor MK-0429 reduces melanoma metastasis,” Oncology Reports, 33(6): 2737-2745 (2015).
[cited by applicant]
Procopiou et al., “Discovery of (S)-3-(3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic α
[cited by applicant]
Prueksaritanont et al., “Disposition of a novel and potent α
[cited by applicant]
Prueksaritanont et al., “Renal elimination of a novel and potent dvB3 integrin antagonist in animals,” Xenobiotica 34(11/12):1059-1074 (2004).
[cited by applicant]
Raab-Westphal et al., “Integrins as Therapeutic Targets: Successes and Cancers, ” Cancers, 9(110):1-28 (2017).
[cited by applicant]
Rosenthal et al., “Evaluation of the safety, pharmacokinetics and treatment effects of an α
[cited by applicant]
Rosenthal et al., “Evaluation of the safety, pharmacokinetics and treatment effects of an α
[cited by applicant]
Rubtsov et al., “RGD-based Therapy: Principles of Selectivity,” Current Pharmaceutical Design, 22: 925-932 (2016).
[cited by applicant]
Santulli et al., “Studies with an Orally Bioavailable α
[cited by applicant]
Schwartz, “Integrins and extracellular matrix in mechanotransduction”, Cold Spring Harbor perspectives in biology 2.12: 1-13, a005066 (2010).
[cited by applicant]
Search Report and Written Opinion for Singaporean Application No. 11201907820S issued Nov. 3, 2020.
[cited by applicant]
Tipping et al., Relative Binding Affinities of Integrin Antagonists by Equilibrium Dialysis and Liquid Chromatography-Mass Spectrometry, Medicinal Chemistry Letters, 6(2): 221-224 (2015).
[cited by applicant]
Wang et al., “Non-peptide α
[cited by applicant]
Whilding et al., “The integrin α
[cited by applicant]
Whitman et al., “Nonpeptide α
[cited by applicant]
Written Opinion for International Application No. PCT/US2017/067622 mailed Mar. 8, 2018.
[cited by applicant]
Written Opinion for International Application No. PCT/US2019/021243 mailed Jul. 5, 2019.
[cited by applicant]
Written Opinion for International Application No. PCT/US2019/039624 mailed Sep. 13, 2019.
[cited by applicant]
Written Opinion for International Application No. PCT/US2019/055252 mailed Jan. 23, 2020.
[cited by applicant]
Zhou et al., “An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model,” Pharmacology Research & Perspectives, 5(5): 1-14 (2017).
[cited by applicant]
Cited By (2)